JP2007531728A - 癌の処置のための5,10−メチレンテトラヒドロ葉酸の使用 - Google Patents

癌の処置のための5,10−メチレンテトラヒドロ葉酸の使用 Download PDF

Info

Publication number
JP2007531728A
JP2007531728A JP2007506303A JP2007506303A JP2007531728A JP 2007531728 A JP2007531728 A JP 2007531728A JP 2007506303 A JP2007506303 A JP 2007506303A JP 2007506303 A JP2007506303 A JP 2007506303A JP 2007531728 A JP2007531728 A JP 2007531728A
Authority
JP
Japan
Prior art keywords
cancer
anticancer drug
additional anticancer
dosage
fluorouracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007506303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007531728A5 (cg-RX-API-DMAC7.html
Inventor
ジョアン エム. ロビンス,
マーク ジェイ. キャントウェル,
Original Assignee
アドベントルクス ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドベントルクス ファーマシューティカルズ, インコーポレイテッド filed Critical アドベントルクス ファーマシューティカルズ, インコーポレイテッド
Publication of JP2007531728A publication Critical patent/JP2007531728A/ja
Publication of JP2007531728A5 publication Critical patent/JP2007531728A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007506303A 2004-04-02 2005-04-01 癌の処置のための5,10−メチレンテトラヒドロ葉酸の使用 Pending JP2007531728A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55888904P 2004-04-02 2004-04-02
US62547904P 2004-11-04 2004-11-04
US65874505P 2005-03-04 2005-03-04
PCT/US2005/011046 WO2005097086A2 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2007531728A true JP2007531728A (ja) 2007-11-08
JP2007531728A5 JP2007531728A5 (cg-RX-API-DMAC7.html) 2008-05-01

Family

ID=35125596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506303A Pending JP2007531728A (ja) 2004-04-02 2005-04-01 癌の処置のための5,10−メチレンテトラヒドロ葉酸の使用

Country Status (7)

Country Link
US (1) US20070280944A1 (cg-RX-API-DMAC7.html)
EP (1) EP1740182A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007531728A (cg-RX-API-DMAC7.html)
AU (1) AU2005231436A1 (cg-RX-API-DMAC7.html)
CA (1) CA2561952A1 (cg-RX-API-DMAC7.html)
IL (1) IL178261A0 (cg-RX-API-DMAC7.html)
WO (1) WO2005097086A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504080A (ja) * 2012-01-20 2015-02-05 アイソフォル・メディカル・エービー Egfr阻害剤と組み合わせたテトラヒドロフォレート
JP2020531490A (ja) * 2017-08-24 2020-11-05 イソフォル メディカル アクティエボラーグ 5−フルオロウラシルに基づく化学療法における[6r]−mthf、有効な葉酸代替物
JP2021510140A (ja) * 2018-01-05 2021-04-15 アイソフォル・メディカル・エービー 大腸癌及び転移性大腸癌を治療する方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871279B2 (en) * 2000-03-09 2014-10-28 Yale University Use of the combination of PHY906 and a tyrosine kinase inhibitor as a cancer treatment regimen
ES2373867T3 (es) 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
WO2008109349A1 (en) * 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
RU2482496C2 (ru) * 2008-09-26 2013-05-20 Эститю Де Кансероложи Де Л'Вест Оптимизация индивидуальных доз 5-фторурацила при режиме folfox
EP2341908B1 (en) * 2008-09-26 2016-04-13 Institut de Cancérologie de l'Ouest (I.C.O) Individual 5-fluorouracile dose optimization in folfiri treatment
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
WO2018065445A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
WO2018065446A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
EP3305318A1 (en) * 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
WO2018150264A1 (en) * 2017-02-14 2018-08-23 Isofol Medical Ab METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534519A (en) * 1990-05-11 1996-07-09 University Of Southern California 5,10,-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
WO2002070008A1 (en) * 2001-03-02 2002-09-12 Imclone Systems Incorporated Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534519A (en) * 1990-05-11 1996-07-09 University Of Southern California 5,10,-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
WO2002070008A1 (en) * 2001-03-02 2002-09-12 Imclone Systems Incorporated Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504080A (ja) * 2012-01-20 2015-02-05 アイソフォル・メディカル・エービー Egfr阻害剤と組み合わせたテトラヒドロフォレート
US9675617B2 (en) 2012-01-20 2017-06-13 Isofol Medical Ab Tetrahydrofolates in combination with EGFR-inhibitors
JP2020531490A (ja) * 2017-08-24 2020-11-05 イソフォル メディカル アクティエボラーグ 5−フルオロウラシルに基づく化学療法における[6r]−mthf、有効な葉酸代替物
JP7356411B2 (ja) 2017-08-24 2023-10-04 イソフォル メディカル アクティエボラーグ 5-フルオロウラシルに基づく化学療法における[6r]-mthf、有効な葉酸代替物
US12527796B2 (en) 2017-08-24 2026-01-20 Isofol Medical Ab [6R]-MTHF—an efficient folate alternative in 5-fluorouracil based chemotherapy
JP2021510140A (ja) * 2018-01-05 2021-04-15 アイソフォル・メディカル・エービー 大腸癌及び転移性大腸癌を治療する方法
JP7258759B2 (ja) 2018-01-05 2023-04-17 アイソフォル・メディカル・エービー 大腸癌及び転移性大腸癌を治療する方法

Also Published As

Publication number Publication date
WO2005097086A3 (en) 2006-05-18
EP1740182A2 (en) 2007-01-10
US20070280944A1 (en) 2007-12-06
WO2005097086A2 (en) 2005-10-20
AU2005231436A1 (en) 2005-10-20
CA2561952A1 (en) 2005-10-20
IL178261A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
EP3735267B1 (en) Adminsitration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy
TWI772354B (zh) 在基於5-氟尿嘧啶的化療中[6r]-亞甲基四氫葉酸的多次推注施用
CA2675451A1 (en) Combination therapy with angiogenesis inhibitors
JP7122256B2 (ja) 血漿2’-デオキシウリジン(dUrd)の増加およびチミジル酸合成酵素阻害のための方法
US20070280944A1 (en) Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
JP2021526161A (ja) 癌治療のための方法及び医薬組成物
Garland et al. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
WO2021080421A1 (en) Novel drug combinations for treatment of a carcinoma
JP6174044B2 (ja) Egfr阻害剤と組み合わせたテトラヒドロフォレート
US20230116137A1 (en) Methods for treating colorectal and metastatic colorectal cancers
KR102032933B1 (ko) 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물
WO2019016928A1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
Fujitani et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer
Camella et al. Emerging role of capecitabine in gastric cancer
Ueda et al. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer
Ricart et al. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
KR20070019725A (ko) 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도
JP2016104703A (ja) 抗腫瘍剤
JP7414230B2 (ja) 抗血液悪性腫瘍薬
Takahashi et al. Feasibility Study of Synchronized Intra-aortic Chemotherapy for Stage IV and Recurrent Gastric Cancer Localized in the Abdominal Cavity
HK40014587A (en) Methods for treating colorectal and metastatic colorectal cancers
HK40040066A (en) Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy
HK40040066B (en) Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111110